U.S. markets closed

ImmunoCellular Therapeutics, Ltd. (IMUC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
0.2450-0.0140 (-5.41%)
At close: 3:44PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.2590
Open0.2375
Bid0.0000 x 900
Ask0.0000 x 3000
Day's Range0.2001 - 0.2589
52 Week Range0.0161 - 0.5100
Volume12,397
Avg. Volume16,817
Market Cap1.186M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-2.6900
Earnings DateAug 24, 2017 - Aug 25, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ImmunoCellular Therapeutics Announces Results of Special Meeting of Stockholders Held June 26, 2020
    PR Newswire

    ImmunoCellular Therapeutics Announces Results of Special Meeting of Stockholders Held June 26, 2020

    ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that, based on the vote count following the Special Meeting of Stockholders held June 26, 2020, stockholders voted in favor of the proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio not less than l-for-3 and not greater than 1-for-10, with the exact ratio to be set within that range at the discretion of its Board of Directors on or before December 31, 2020 without further approval or authorization of its stockholders.